Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD1 | P21728 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | TDO2 | P48775 | 1/20 | 0.35 |
| ▸ | FDPS | P14324 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10297581 | 1.00 | SIGMAR1 (0.38) | SIGMAR1CHRNB2CHRNA4CHRNA7DRD2 | |
| SCHEMBL8225223 | 0.90 | CHRNB2 (0.46) | SIGMAR1CHRNB2CHRNA4CHRNA7IDO1 | |
| SCHEMBL2669659 | 0.86 | CHRNB2 (0.49) | SIGMAR1CHRNB2CHRNA4CHRNA7DRD2 | |
| SCHEMBL19044027 | 0.77 | IDO1 (0.43) | SIGMAR1CHRNB2CHRNA4CHRNA7DRD2 | |
| SCHEMBL14161103 | 0.77 | CYP19A1 (0.44) | SIGMAR1DRD2HTR2AHTR2CHTR2B | |
| SCHEMBL10297549 | 0.76 | CHRNB2 (0.58) | SIGMAR1CHRNB2CHRNA4CHRNA7FDPS | |
| SCHEMBL15386162 | 0.76 | IDO1 (0.43) | SIGMAR1CHRNB2CHRNA4CHRNA7DRD2 | |
| SCHEMBL30251479 | 0.76 | IDO1 (0.43) | SIGMAR1CHRNB2CHRNA4CHRNA7DRD2 | |
| SCHEMBL18816531 | 0.76 | IDO1 (0.43) | SIGMAR1CHRNB2CHRNA4CHRNA7DRD2 | |
| SCHEMBL10297727 | 0.76 | SIGMAR1 (0.42) | SIGMAR1CHRNB2CHRNA4CHRNA7DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159543-A1 | ANTHELMINTIC PYRROLOPYRIDAZINE COMPOUNDS | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159543-A1 | ANTHELMINTIC PYRROLOPYRIDAZINE COMPOUNDS | IL5, EPX, MPO | SIGMAR1 4760/4885CHRNB2 4449/4885CHRNA4 3856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.